Codice QR

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

Introduction: Durvalumab after concurrent chemoradiation (CCRT) for NSCLC improves survival, but only in a subset of patients. We investigated the effect of severe radiation-induced lymphopenia (sRIL) on survival in these patients. Methods: Outcomes after CCRT (2010–2019) or CCRT followed by durvalu...

Descrizione completa

Salvato in:
Autori principali: Wang Jing, MD, Ting Xu, PhD, Lirong Wu, MD, Pablo B. Lopez, MD, Clemens Grassberger, PhD, Susannah G. Ellsworth, MD, Radhe Mohan, PhD, Brian P. Hobbs, PhD, George R. Blumenschein, MD, Janet Tu, MD, Mehmet Altan, MD, Percy Lee, MD, Zhongxing Liao, MD, Steven H. Lin, MD, PhD
Natura: Artigo
Lingua:Inglês
Pubblicazione: Elsevier 2022-09-01
Serie:JTO Clinical and Research Reports
Soggetti:
NSCLC
Lymphopenia
Radiation
Immunotherapy
Durvalumab
Consolidative therapy
Accesso online:http://www.sciencedirect.com/science/article/pii/S2666364322001151
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi